TENOFOVIR DISOPROXIL FUMARATE
Tenofovir Disoproxil Fumarate (TDF) is an antiretroviral medication belonging to the nucleotide reverse transcriptase inhibitor (NRTI) class. It is a prodrug of tenofovir, used primarily in the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection.- Treatment of HIV-1 infection in adults and pediatric patients in combination with other antiretroviral agents. - Treatment of chronic hepatitis B in adults and pediatric patients aged 2 years and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.
- HIV-1 Infection (Adults): 300 mg once daily with or without food. - Chronic Hepatitis B (Adults): 300 mg once daily. - Pediatric Dosage: Weight-based dosing; follow prescribing information. Note: Dosage may require adjustment in patients with renal impairment.
Known hypersensitivity to tenofovir disoproxil fumarate or any component of the formulation.
- Monitor renal function periodically, especially in patients at risk of renal impairment. - Risk of lactic acidosis and severe hepatomegaly with steatosis. - Monitor bone mineral density in patients at risk of osteoporosis. - Risk of exacerbation of hepatitis after discontinuation in HBV-infected patients. - Use with caution in patients co-infected with HIV and HBV.
Common side effects include : - Nausea , Diarrhea, Headache, Fatigue , Rash , Depression Serious adverse effects: - Renal toxicity, including acute renal failure and Fanconi syndrome - Decreased bone mineral density - Lactic acidosis - Hepatomegaly with steatosis
- Increased risk of nephrotoxicity with concurrent use of nephrotoxic drugs (e.g., aminoglycosides, NSAIDs). - Avoid combination with other drugs containing tenofovir or adefovir dipivoxil. - May reduce concentrations of certain antiretrovirals when co-administered.
